Efficacy results were assessed using missing or discontinuation equals failure (MD = F) analyses, in which missing assessments were considered failures, and observed analyses, in which missing assessments at any scheduled time point were considered unevaluable and were not imputed.
In a sensitivity analysis using missing or discontinuation = failure (MD = F), the response rates were typically higher than using TLOVR (87, 80, and 86% for DTG 50, 25, and 10 mg, respectively), which mainly reflects the participants who were resuppressed after prior rebound.
Each study also examined time to treatment or to efficacy-related discontinuation or failure (TRDF and ERDF).
The most common reasons for discontinuation were failure to meet the confirmation of enrollment criteria, withdrawal of consent or physician-determined withdrawal prior to treatment assignment.
In particular, our analysis was focused on the following causes of EFV discontinuation: virological failure, toxicity, CNS-SE, patient's decision.
Conventional multiple logistic regression analyses were also performed to confirm the impact of the studied platinum-based doublets on early treatment discontinuation, treatment failure, and hematological AE using vinorelbine/platinum as reference.
Further multiple logistic regression analyses with generalized estimating equation adjusted imbalanced baseline variables (p < 0.5 after matching) in propensity score matched patients [ 16] to confirm the head-to-head comparisons of early treatment discontinuation, treatment failure, and hematological AEs.
1,691 patients with complete information on patient baseline characteristics and hematological AE management were included for the assessment on the risks of early treatment discontinuation, treatment failure, and hematological AEs associated with the five studied platinum-based doublets.
Finally, our study used conventional multiple logistic regression analyses to rank the impact of the five studied doublets using vinorelbine/platinum as reference on the risks of early treatment discontinuation, treatment failure, and hematological AEs after the adjustment of patient baseline characteristics, platinum agent used in doublet, and hematological AE management.
Of the 60 patients who discontinued prior to 52 weeks, the reasons for discontinuation were: treatment failure (40%, 27/67 patients); AEs (15%, 10/67 patients); major protocol violation (3.0%, 2/67 patients); non-compliance (3.0%, 2/67 patients); lost to follow up (1.5%, 1/67 patients); or 'other reasons' (27%, 18/67 patients).
